DNM1L and breast carcinoma: DRP1-targeting using the Mitochondrial division inhibitor 1 (Mdivi-1) resensitizes chemoresistant hepatocellular carcinoma, lung, and breast cancer cell lines to cytotoxic cisplatin treatment [145].